Persistent brain metabolic impairment in long COVID patients with persistent clinical symptoms: a nine-month follow-up [18F]FDG-PET study
European Journal of Nuclear Medicine and Molecular Imaging · 2024-09 · 51 (11) · 3215-3222
DOI: 10.1007/s00259-024-06775-x ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 12.06.2024. Verfasst von Tatiana Horowitz und 8 weiteren Autor:innen. Beteiligte Einrichtung: APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix-Marseille University, 264 rue Saint-Pier…. Hauptthemen laut MEDLINE: COVID-19, Fluorodeoxyglucose F18, Brain, Positron-Emission Tomography. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: PHRC.
Abstract (Originalsprache)
PURPOSE: A hypometabolic profile involving the limbic areas, brainstem and cerebellum has been identified in long COVID patients using [18F]fluorodeoxyglucose (FDG)-PET. This study was conducted to evaluate possible recovery of brain metabolism during the follow-up of patients with prolonged symptoms. METHODS: Fifty-six adults with long COVID who underwent two brain [18F]FDG-PET scans in our department between May 2020 and October 2022 were retrospectively analysed, and compared to 51 healthy subjects. On average, PET1 was performed 7 months (range 3-17) after acute COVID-19 infection, and PET2 was performed 16 months (range 8-32) after acute infection, because of persistent severe or disabling symptoms, without significant clinical recovery. Whole-brain voxel-based analysis compared PET1 and PET2 from long COVID patients to scans from healthy subjects (p-voxel < 0.001 uncorrected, p-cluster < 0.05 FWE-corrected) and PET1 to PET2 (with the same threshold, and secondarily with a less constrained threshold of p-voxel < 0.005 uncorrected, p-cluster < 0.05 uncorrected). Additionally, a region-of-interest (ROI) semiquantitative anatomical approach was performed for the same comparisons (p < 0.05, corrected). RESULTS: PET1 and PET2 revealed voxel-based hypometabolisms consistent with the previously reported profile in the literature. This between-group analysis comparing PET1 and PET2 showed minor improvements in the pons and cerebellum (8.4 and 5.2%, respectively, only significant under the less constrained uncorrected p-threshold); for the pons, this improvement was correlated with the PET1-PET2 interval (r = 0.21, p < 0.05). Of the 14,068 hypometabolic voxels identified on PET1, 6,503 were also hypometabolic on PET2 (46%). Of the 7,732 hypometabolic voxels identified on PET2, 6,094 were also hypometabolic on PET1 (78%). The anatomical ROI analysis confirmed the brain hypometabolism involving limbic region, the pons and cerebellum at PET1 and PET2, without significant changes between PET1 and PET2. CONCLUSION: Subjects with persistent symptoms of long COVID exhibit durable deficits in brain metabolism, without progressive worsening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix-Marseille University, 264 rue Saint-Pierre, Marseille, 13005, France.
- IHU Méditerranée Infection, APHM, Marseille, France.
- CHU Tours, Tours, France, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix-Marseille University, Marseille, France.
- APHM, Service de Médecine interne, Conception Hospital, Marseille, France.
- Department of Oto-Rhino- Laryngology, Aix-Marseille University, APHM, IUSTI, Conception Hospital, Marseille, France.
- APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix-Marseille University, 264 rue Saint-Pierre, Marseille, 13005, France. eric.guedj@ap-hm.fr.
ORCID-Profile: Eric Guedj
Förderung
- PHRC
Zitieren
APA
Horowitz, T., Dudouet, P., Campion, J. Y., Kaphan, E., Radulesco, T., Gonzalez, S., Cammilleri, S., Ménard, A., & Guedj, E. (2024). Persistent brain metabolic impairment in long COVID patients with persistent clinical symptoms: a nine-month follow-up [18F]FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging, 51(11), 3215-3222. https://doi.org/10.1007/s00259-024-06775-x
Vancouver
Horowitz T, Dudouet P, Campion JY, Kaphan E, Radulesco T, Gonzalez S, et al. Persistent brain metabolic impairment in long COVID patients with persistent clinical symptoms: a nine-month follow-up [18F]FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(11):3215-3222. doi:10.1007/s00259-024-06775-x
BibTeX
@article{Horowitz2024,
author = {Horowitz, Tatiana and Dudouet, Pierre and Campion, Jacques-Yves and Kaphan, Elsa and Radulesco, Thomas and Gonzalez, Sandra and Cammilleri, Serge and Ménard, Amélie and Guedj, Eric},
title = {Persistent brain metabolic impairment in long COVID patients with persistent clinical symptoms: a nine-month follow-up [18F]FDG-PET study},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
volume = {51},
number = {11},
pages = {3215--3222},
doi = {10.1007/s00259-024-06775-x}
}
EUVIMED